Pfizer (NYSE:PFE) Trading Up 1.3% – Should You Buy?

Shares of Pfizer Inc. (NYSE:PFE) were up 1.3% during trading on Tuesday . The stock traded as high as $25.96 and last traded at $25.6640. Approximately 40,929,096 shares were traded during trading, a decline of 3% from the average daily volume of 42,348,012 shares. The stock had previously closed at $25.33.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a new Phase 3 endometrial cancer trial, a sign the company is still advancing its oncology pipeline and trying to compete more directly with larger cancer drug players like Merck. Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Several recent commentary pieces argue Pfizer remains undervalued, with analysts and market-watch articles pointing to its relatively low valuation and stable balance sheet as reasons investors may be willing to buy the stock. Why Pfizer Stock Still Looks Deeply Undervalued In 2026
• Neutral Sentiment: Pfizer is also getting attention from general stock screens and “under $30” lists, which tends to keep it on investors’ radar but does not represent a direct business catalyst. The SoFi CEO Just Bought 70000 Shares With His Own Money Here Are Four More Under 30 Worth a Closer Look
• Neutral Sentiment: Analyst sentiment remains cautious, with Pfizer receiving a consensus “Hold” rating, suggesting Wall Street sees limited near-term upside despite the company’s defensive profile. Pfizer Inc Receives Consensus Recommendation of Hold from Analysts
• Negative Sentiment: Pharma stocks, including Pfizer, were recently pressured by news that TrumpRx may see a “dramatic expansion,” reviving investor worries about drug pricing pressure and margins across the sector. PFE NVO LLY Pharma Stocks Drop on News TrumpRx Set for Dramatic Expansion

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PFE shares. Citigroup increased their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. HSBC increased their price target on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. UBS Group increased their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Monday, April 13th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.84.

Pfizer Stock Up 1.3%

The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock’s fifty day simple moving average is $26.96 and its 200-day simple moving average is $26.20. The stock has a market cap of $146.27 billion, a P/E ratio of 19.59 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the company posted $0.92 earnings per share. Pfizer’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently made changes to their positions in PFE. Horizon Financial Services LLC raised its holdings in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. YANKCOM Partnership bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC raised its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. increased its stake in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.